Bell Potter sets AUD 4.40 target for Mesoblast stock

Published on 10/20/2026 at 18:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ryoncil sales were USD 28.00 million versus a USD 40.00 million forecast. Mesoblast stock costs EUR 1.12 on October 20, 2026.

Broker view and operating figures

Bell Potter kept its buy rating and set a AUD 4.40 target on October 19, 2026.
Ryoncil sales were USD 28.00 million against a USD 40.00 million forecast.
Mesoblast stock costs EUR 1.12 at Lang & Schwarz on October 20, 2026 at 6:30 p.m. CEST.
Fiscal 2026 revenue reached USD 120.30 million, compared with USD 17.20 million in fiscal 2025.

MESO, AU000000MSB8, Illustration mit AI erstellt.

Bell Potter retained its buy rating and set a AUD 4.40 target for Mesoblast on October 19, 2026, after the biotechnology company reported Ryoncil sales of USD 28.00 million against a USD 40.00 million forecast, according to The Motley Fool Australia. Mesoblast was trading at EUR 1.12 at Lang & Schwarz on October 20, 2026 at 6:30 p.m. CEST.

Ryoncil sales set the near-term test

The September-quarter sales figure was 30.00 percent below Bell Potter's forecast, based on USD 28.00 million compared with USD 40.00 million. The broker attributed the shortfall to low patient numbers during the summer months, with August identified as the low point.

Nasdaq range keeps the stock in view

On Nasdaq, Mesoblast was last at USD 12.38 on October 20, 2026 at 12:32 p.m. ET. The finance profile lists a market capitalization of USD 1.6 billion, while the 52-week range stood at USD 9.88 to USD 21.50. Mesoblast's Nasdaq listing consists of American depositary shares under the ticker MESO, with each share representing ten ordinary shares, as stated in the company's fiscal 2026 filing carried by StockTitan.

Revenue growth meets funding risk

Mesoblast reported USD 120.30 million in fiscal 2026 revenue, up from USD 17.20 million in fiscal 2025, while Ryoncil generated USD 115.20 million in net product sales. The same fiscal report listed USD 43.80 million in net operating cash use, USD 102.90 million in cash and a USD 125.00 million five-year credit facility. It also reported a USD 57.50 million net loss for the year ended June 30, 2026. The report said the chronic low back pain Phase 3 trial completed treatment of 350 patients, with clinical endpoints expected in the second half of calendar 2027.

Mesoblast stock and the broker target

Bell Potter's retained buy rating contrasts with the weaker September-quarter sales outcome. For investors, the key balance is whether broader Ryoncil adoption can offset the near-term revenue shortfall while Mesoblast funds late-stage clinical programs.

Trading level in euros

The stock was trading at EUR 1.12 at Lang & Schwarz on October 20, 2026 at 6:30 p.m. CEST. The Nasdaq quote was USD 12.38 at 12:32 p.m. ET on the same date, a separate home-market view.

The further course of trading is shown by the continuously updated real-time quote of Mesoblast stock.